Genpact (G) Rebounds Over 3 Months, Is The Stock Still Cheap?

Genpact (G) has drawn fresh attention after recent trading left the stock about 10% lower over the past month, even as the past 3 months show a gain of roughly 22%.

Set against a 1-year total shareholder return that is down 19.13% and a 5-year total shareholder return that is lower by 23.86%, Genpact’s recent 22.33% 3-month share price return looks like a short-term rebound rather than a clear shift in longer-term sentiment, especially with the share price at $33.85 after a 30-day share price return that declined 9.95% and a year-to-date share price return that is down 26.27% as investors reassess both growth prospects and risk around the current valuation.

Compare Genpact’s recent swing with a curated 30 high quality undervalued stocks that also pair sharp share price moves with stronger fundamentals.

Genpact trades at a steep implied discount to both analyst targets and some intrinsic value estimates after a sharp rebound. Is this genuine mispricing, or is the market’s caution about the business now doing the heavier lifting?

Most Popular Narrative: 20% Undervalued

Genpact’s most followed narrative pegs fair value at $42.18 using a 7.82% discount rate, compared with the recent close at $33.85, which frames the recent rebound as a move that still leaves a sizeable valuation gap on these assumptions.

The rising share of annuitized, non FTE and outcome based contracts, with non FTE revenue surpassing 50% of total revenue in Q2 2026 and more than 70% of ATS revenue both annuitized and non FTE, increases the potential for more recurring revenue and steadier earnings over time.

See why 20 investors see Genpact as 20% undervalued.

Result: Fair Value of $42.18 (UNDERVALUED)

Still, Genpact’s active exit from lower value contracts and the share price drop after Q2 2026 both point to execution and confidence risks around this undervaluation story.

Find out about the key risks to this Genpact narrative.

Next Steps

Sentiment on Genpact is split, and that is exactly when doing your own homework matters most. Move quickly and weigh both the red flags and bright spots by checking the 5 key rewards and 1 important warning sign.

Looking for more Genpact style investment ideas?

If Genpact has you rethinking where you focus your capital, do not stop here. Use the Simply Wall Street Screener to spot fresh opportunities before other investors catch on.

• Target resilience first by scanning a 31 resilient stocks with low risk scores that prioritises robust fundamentals and lower downside potential.
• Hunt for quality at a discount through a curated 16 high quality undiscovered gems that flags strong businesses the crowd has largely ignored so far.
• Rebalance toward sturdier finances by filtering a list of solid balance sheet and fundamentals (23 results) that highlights companies with cleaner leverage and healthier liquidity profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com